Dilatrend SR (carvedilol sustained release) / Chong Kun Dang - LARVOL DELTA

PROVE: Pharmacological Reduction of Right Ventricular Enlargement (clinicaltrials.gov) - P3 | N=58 | Completed | Sponsor: Asan Medical Center | Active, not recruiting ➔ Completed | N=180 ➔ 58 | Trial completion date: Dec 2024 ➔ Jun 2024 | Trial primary completion date: Dec 2024 ➔ Jun 2024

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Congestive Heart Failure

PROVE: Pharmacological Reduction of Right Ventricular Enlargement (clinicaltrials.gov) - P3 | N=180 | Active, not recruiting | Sponsor: Asan Medical Center | Recruiting ➔ Active, not recruiting

Enrollment closed • Congestive Heart Failure

The effect of sustained-release CARvedilol in patients with hypErtension and heart failure with preserved ejection fraction: a study protocol for a pilot randomized controlled trial (CARE-preserved HF). (PubMed, Front Cardiovasc Med) - P4 | "This randomized controlled trial will investigate the efficacy and safety of carvedilol-SR in patients with HFpEF and hypertension. ClinicalTrial.gov, identifier NCT05553314."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension

PROVE: Pharmacological Reduction of Right Ventricular Enlargement (clinicaltrials.gov) - P3 | N=180 | Recruiting | Sponsor: Asan Medical Center | Trial completion date: May 2024 ➔ Dec 2024 | Trial primary completion date: May 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • Congestive Heart Failure

Carvedilol in HF With Reduced Strain and Preserved EF (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: Seoul National University Bundang Hospital

New P4 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

PROVE: Pharmacological Reduction of Right Ventricular Enlargement (clinicaltrials.gov) - P3 | N=180 | Recruiting | Sponsor: Asan Medical Center | Trial completion date: May 2023 ➔ May 2024 | Trial primary completion date: May 2023 ➔ May 2024

Trial completion date • Trial primary completion date • Congestive Heart Failure

Clinical Characteristics and Outcome of Immediate-Release Versus SLOW-Release Carvedilol in Heart Failure Patient (SLOW-HF): a Prospective Randomized, Open-Label, Multicenter Study. (PubMed, Cardiovasc Drugs Ther) - P4 | "Carvedilol-SR once a day was non-inferior to carvedilol-IR twice a day in patients with HFrEF."

Clinical • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

PROVE: Pharmacological Reduction of Right Ventricular Enlargement (clinicaltrials.gov) - P3; N=180; Recruiting; Sponsor: Asan Medical Center; Not yet recruiting ➔ Recruiting; Initiation date: Aug 2020 ➔ Jan 2021

Clinical • Enrollment open • Trial initiation date • Congestive Heart Failure • MRI